Richard Saunders, MD
Pulmonary Disease · Pottstown, PANPI 1528111069
Payments from drug & device makers
Across 184 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$665
- AstraZeneca$416
- Novo Nordisk$185
- Johnson & Johnson$172
- Amgen$156
- Philips North America LLC$142
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,230100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 34 | $665 |
| AstraZeneca | 16 | $416 |
| Novo Nordisk | 12 | $185 |
| Johnson & Johnson | 9 | $172 |
| Amgen | 9 | $156 |
| Philips North America LLC | 10 | $142 |
| Merck | 10 | $140 |
| AbbVie | 7 | $136 |
| Boehringer Ingelheim | 8 | $133 |
| Pfizer | 10 | $127 |
| Lilly USA, LLC | 8 | $118 |
| Sanofi-aventis U.S. LLC | 6 | $104 |
| Jazz Pharmaceuticals Inc. | 5 | $93 |
| Astellas Pharma US Inc | 5 | $80 |
| Regeneron Healthcare Solutions, Inc. | 5 | $63 |
| Circassia Inc. | 4 | $56 |
| Medtronic | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Sanofi | 2 | $44 |
| Mylan Specialty L.p. | 2 | $39 |
| Novartis | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Eisai Inc. | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Biogen | 1 | $21 |
| Vivus LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Edwards Lifesciences | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,230 in reported general payments places this provider in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 251 | $277,807 |
| Breo ElliptaFluticasone/Vilanterol | 144 | $101,625 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 114 | $85,595 |
| EliquisApixaban | 76 | $60,273 |
| XareltoRivaroxaban | 68 | $52,720 |
| Spiriva RespimatTiotropium Bromide | 57 | $52,638 |
| JanuviaSitagliptin Phosphate | 35 | $51,511 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $44,677 |
| Incruse ElliptaUmeclidinium Bromide | 53 | $27,557 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $22,457 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 122 | $20,764 |
| Advair HfaFluticasone Propion/Salmeterol | 34 | $19,306 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $18,222 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 509 | $15,629 |
| Wixela InhubFluticasone Propion/Salmeterol | 34 | $8,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $665 | $492,585562 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $133 | $70,86074 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $416 | $67,134101 claims |
| PfizerEliquis | $127 | $60,27376 claims |
| MerckJanuvia, Dulera | $140 | $59,53952 claims |
| Johnson & JohnsonXarelto | $172 | $52,72068 claims |
| AbbVieSynthroid | $136 | $1,63316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Pottstown
- An PhamPottstown$174K
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.